Liquid Biopsy (ctDNA) Guided Treatment in Localized Pancreatic Cancer: Neoadjuvant CTX vs. Upfront Surgery

Launched by ELISABETHINEN HOSPITAL · Apr 25, 2024

Keywords

ClinConnect Summary

This clinical trial is studying how well a new approach using a liquid biopsy (a simple blood test that detects cancer DNA) can guide treatment for patients with localized pancreatic cancer. The trial compares this new method to the standard treatment, which usually involves surgery right away. For patients who test positive for cancer DNA in their blood, the study suggests they receive chemotherapy first to lower the risk of the cancer coming back before considering surgery. This is important because some tumors may have a higher risk of recurrence after surgery.

To participate in this trial, you need to be at least 18 years old and have localized pancreatic cancer that would normally require surgery. However, if you have another active cancer or are pregnant, you won't be eligible. If you join the trial, you can expect close monitoring and a chance to contribute to new treatment options that might improve outcomes for future patients with pancreatic cancer. The study is currently recruiting participants, and everyone is welcome, regardless of gender.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • Informed consent
• • \>18 years old
• • localized pancreatic cancer to go for upfront surgery
• Exclusion Criteria:
• • synchronous secondary malignancy
• • pregnancy